Skip to content

Dianthus Therapeutics DNTH Net Change in Cash

Net Change in Cash at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Amgen logo
AmgenAMGN
$2.91B+192%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$11.46M+128%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$212.91M-603%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$65.32M+54.0%
TG Therapeutics logo
TG TherapeuticsTGTX
$363.07M+860%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's net change in cash?
Dianthus Therapeutics (DNTH) reported net change in cash of $576.58M in Q1 2026.
How has Dianthus Therapeutics's net change in cash changed year-over-year?
Dianthus Therapeutics's net change in cash increased by 4649.0% year-over-year, from -$12.68M to $576.58M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.